Literature DB >> 29741098

Monophosphoryl lipid A prevents impairment of medullary thick ascending limb [Formula: see text] absorption and improves plasma [Formula: see text] concentration in septic mice.

Bruns A Watts1, Thampi George1, Edward R Sherwood2, David W Good1,3.   

Abstract

Metabolic acidosis is the most common acid-base disorder in septic patients and is associated with increased mortality. Previously, we demonstrated that sepsis induced by cecal ligation and puncture (CLP) impairs [Formula: see text] absorption in the medullary thick ascending limb (MTAL) by 1) decreasing the intrinsic [Formula: see text] absorptive capacity and 2) enhancing inhibition of [Formula: see text] absorption by LPS through upregulation of Toll-like receptor (TLR) 4 signaling. Both effects depend on ERK activation. Monophosphoryl lipid A (MPLA) is a detoxified TLR4 agonist that enhances innate antimicrobial immunity and improves survival following sepsis. Pretreatment of MTALs with MPLA in vitro prevents LPS inhibition of [Formula: see text] absorption. Here we examined whether pretreatment with MPLA would protect the MTAL against sepsis. Vehicle or MPLA was administered to mice 48 h before sham or CLP surgery, and MTALs were studied in vitro 18 h postsurgery. Pretreatment with MPLA prevented the effects of sepsis to decrease the basal [Formula: see text] absorption rate and enhance inhibition by LPS. These protective effects were mediated through MPLA stimulation of a Toll/IL-1 receptor domain-containing adaptor-inducing IFN-β-(TRIF)-dependent phosphatidylinositol 3-kinase-Akt pathway that prevents sepsis- and LPS-induced ERK activation. The effects of MPLA to improve MTAL [Formula: see text] absorption were associated with marked improvement in plasma [Formula: see text] concentration, supporting a role for the kidneys in the pathogenesis of sepsis-induced metabolic acidosis. These studies support detoxified TLR4-based immunomodulators, such as MPLA, that enhance antimicrobial responses as a safe and effective approach to prevent or treat sepsis-induced renal tubule dysfunction and identify cell signaling pathways that can be targeted to preserve MTAL [Formula: see text] absorption and attenuate metabolic acidosis during sepsis.

Entities:  

Keywords:  LPS; kidney; metabolic acidosis; monophosphoryl lipid A; sepsis

Mesh:

Substances:

Year:  2018        PMID: 29741098      PMCID: PMC6172583          DOI: 10.1152/ajprenal.00033.2018

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  84 in total

1.  IRAK-M is a negative regulator of Toll-like receptor signaling.

Authors:  Koichi Kobayashi; Lorraine D Hernandez; Jorge E Galán; Charles A Janeway; Ruslan Medzhitov; Richard A Flavell
Journal:  Cell       Date:  2002-07-26       Impact factor: 41.582

Review 2.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Nat Immunol       Date:  2010-04-20       Impact factor: 25.606

Review 3.  Sepsis and the kidney.

Authors:  Jennifer Klenzak; Jonathan Himmelfarb
Journal:  Crit Care Clin       Date:  2005-04       Impact factor: 3.598

Review 4.  Clinical approach to the patient with AKI and sepsis.

Authors:  Mélanie Godin; Patrick Murray; Ravindra L Mehta
Journal:  Semin Nephrol       Date:  2015-01       Impact factor: 5.299

Review 5.  Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant.

Authors:  C R Casella; T C Mitchell
Journal:  Cell Mol Life Sci       Date:  2008-10       Impact factor: 9.261

6.  Monophosphoryl lipid A protects against gram-positive sepsis and tumor necrosis factor.

Authors:  M E Astiz; A Galera; D C Saha; C Carpati; E C Rackow
Journal:  Shock       Date:  1994-10       Impact factor: 3.454

Review 7.  Molecular mechanisms of endotoxin tolerance.

Authors:  Hongkuan Fan; James A Cook
Journal:  J Endotoxin Res       Date:  2004

Review 8.  The immunobiology of toll-like receptor 4 agonists: from endotoxin tolerance to immunoadjuvants.

Authors:  Julia K Bohannon; Antonio Hernandez; Perenlei Enkhbaatar; William L Adams; Edward R Sherwood
Journal:  Shock       Date:  2013-12       Impact factor: 3.454

9.  Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: a prospective, double-blind, randomized, controlled trial.

Authors:  M E Astiz; E C Rackow; J G Still; S T Howell; A Cato; K B Von Eschen; J T Ulrich; J A Rudbach; G McMahon; R Vargas
Journal:  Crit Care Med       Date:  1995-01       Impact factor: 7.598

10.  TRIF is required for TLR4 mediated adjuvant effects on T cell clonal expansion.

Authors:  Siva K Gandhapudi; Paula M Chilton; Thomas C Mitchell
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

View more
  3 in total

1.  Monophosphoryl lipid A pretreatment suppresses sepsis- and LPS-induced proinflammatory cytokine production in the medullary thick ascending limb.

Authors:  Bruns A Watts; Esther Tamayo; Edward R Sherwood; David W Good
Journal:  Am J Physiol Renal Physiol       Date:  2020-05-18

2.  Monophosphoryl lipid A induces protection against LPS in medullary thick ascending limb through induction of Tollip and negative regulation of IRAK-1.

Authors:  Bruns A Watts; Esther Tamayo; Edward R Sherwood; David W Good
Journal:  Am J Physiol Renal Physiol       Date:  2019-06-26

3.  Lipopolysaccharide directly inhibits bicarbonate absorption by the renal outer medullary collecting duct.

Authors:  Shuichi Tsuruoka; Jeffrey M Purkerson; George J Schwartz
Journal:  Sci Rep       Date:  2020-11-25       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.